Uncategorized

Pound for Pound

This has been an interesting week in Spine/Biologics. You may remember when Ramius decided to go on the offensive against Orthofix last year regarding the perceived mismanagement/acquisition of Blackstone. Apparently, some other investors thought highly of that tactic as investors of Alphatec and Osteotech have decided to employ a similar strategy. Osteotech has started their process in a similar way, with a written letter slamming the contributions of its current CEO and executive management team. Alphatec investors, however, decided to play even more hardball by expressing their desire to investigate “insider trading” and “misleading information provided to investors” with some of the company’s Directors.

We are curious to know what you all know. Is this just another controlling investment group trying to forcefully impose its will on a public company, or is there fire where there appears to be smoke.

Please leave the information you are aware of to spur conversation regarding this topic.

Josh Sandberg

Josh Sandberg is the President and CEO of Ortho Spine Partners and sits on several company and industry related Boards. He also is the Creator and Editor of OrthoSpineNews.

Related Articles

Back to top button